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AbstrAct
Aim To assess the rate of ’treatment-requiring diabetic 
macular oedema (DMO)’ in eyes for the two  years before 
and after cataract surgery.
Methods Multicentre national diabetic retinopathy (DR) 
database study with anonymised data extraction across 
19 centres from an electronic medical record system. 
Inclusion criteria: eyes undergoing cataract surgery in 
patients with diabetes with no history of DMO prior to 
study start. The minimum dataset included: age, visual 
acuity (all time-points), injection episodes, timing of 
cataract surgery and ETDRS grading of retinopathy and 
maculopathy. Main outcome measure: rate of developing 
first episode of treatment-requiring DMO in relation to 
timing of cataract surgery in the same eye.
results 4850 eyes met the inclusion criteria. The rate of 
developing treatment-requiring DMO in this cohort was 
2.9% in the year prior to surgery versus 5.3% in the year 
after surgery (p<0.01). The risk of ’treatment-requiring 
DMO’ increased sharply after surgery, peaking in the 3–6 
months’ period (annualised rates of 5.2%, 6.8%, 5.6% 
and 4.0% for the 0–3, 3–6, 6–9 and 9–12 months’ 
post-operative time periods respectively). Risk was 
associated with pre-operative grade of retinopathy: risk 
of DMO in the first year post-operatively being 1.0% (no 
DR pre-operatively), 5.4% (mild non-proliferative diabetic 
retinopathy; NPDR), 10.0% (moderate NPDR), 13.1% 
(severe NPDR) and 4.9% (PDR) (p<0.01).
conclusions This large real-world study demonstrates 
that the rate of developing treatment-requiring DMO 
increases sharply in the year after cataract surgery for 
all grades of retinopathy, peaking in the 3–6 months’ 
postoperative period. Patients with moderate and severe 
NPDR are at particularly high risk.
IntroductIon
Visually significant cataract is a common problem 
in people with diabetes, occurring earlier and with 
a prevalence of 2–5 times that of the population 
without diabetes.1–3 Cataract surgery is known to 
lead to increased levels of inflammatory mediators 
such as prostaglandins, thromboxane A, nitric acid 
and various cytokines in addition to vascular endo-
thelial growth factor (VEGF).4–7 Patel et al4 showed 
that some of these changes are present within  1 day 
of surgery and do not return to normal for several 
weeks. Retinovascular changes also occur, including 
vascular hyperpermeability and leukostasis.4–6 8
Despite these recognised changes in the ocular 
microenvironment, clinical studies are incon-
clusive as to the effect of cataract surgery on 
the onset of diabetic macular oedema (DMO). 
Furthermore there is quite marked variation in the 
rates of DMO reported in such studies, which may 
reflect study design, variable definition of DMO, 
and the population sampled. Most studies in this 
area are small with fewer than 100 patients.9–13 An 
important exception is ETDRS Report 25 which 
analysed the subset of 270 eyes (205 patients) who 
underwent cataract surgery during the course of 
the prospective ETDRS randomised controlled 
trial (RCT). These patients with non-proliferative 
diabetic retinopathy (NPDR) had mild to severe 
or early proliferative diabetic retinopathy (PDR) 
and/or macular oedema. This was a post-hoc anal-
ysis of patients who happened to undergo cataract 
surgery during the study period without stan-
dardisation of timing or perioperative manage-
ment. With regard to macular oedema the defined 
endpoint was clinically significant macular oedema 
(CSME), which was defined without the use of 
optical coherence tomography (OCT) imaging and 
was based on the clinical endpoint of stereoscopic 
fundus photography. This study showed no signif-
icant increase in the rate of CSME with 29% of 
patients having CSME at the study visit prior to 
cataract surgery and 31% having CSME post-sur-
gery.9 A more recent prospective study looking at 
unilateral cataract surgery in 132 eyes (with the 
fellow eye acting as control) noted a trend towards 
a higher rate of CSME in the operated eye versus 
the fellow eye (6.1% vs 4.5%). In this study all 
patients had 3 monthly fluorescein angiography; 
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OCT was not performed in all patients but only those with 
suspected CSME.12
The use of electronic medical record (EMR) systems which 
routinely gather clinically relevant data provides the opportunity 
to analyse larger study cohorts than would be practical within 
a clinical trial. In the UK, the most widely-used ophthalmic 
EMR has implemented a nationally-defined minimum dataset 
for diabetic retinopathy (DR) that mandates recording of the 
minimum clinical signs necessary to allow an algorithm within 
the software to automatically calculate a precise proxy-ETDRS/
International Clinical Grading System retinopathy and maculop-
athy grade after each consultation (as described in UK DR EMR 
Report 1  appendix 1).14 All interventions including laser proce-
dures, intravitreal injections and ophthalmic operations are 
recorded, providing the opportunity to assess whether the rate 
of treatment-requiring DMO is influenced by cataract surgery 
in a large ‘real-world’ cohort. In the UK, the National Health 
Service (NHS) use of ranibizumab is regulated by the National 
Institute for Health and Care Excellence (NICE), with treat-
ment only being funded for DMO where it is demonstrated on 
OCT to be associated with a central macular thickness (CMT) 
of over 400 microns.15 It is important to note that CMT is not 
precisely defined as, for example, subfoveal thickness or central 
grid thickness. Random audits of ranibizumab use by commis-
sioners have the potential to withdraw funding, so there is a 
strong motivation for physicians to comply with the guidance. 
It is also important to note that there is no visual acuity level 
specified in the NICE guidance. Due to this unique regulatory 
framework, the assessment of ‘Ranibizumab-requiring DMO’ 
in the UK therefore provides a surrogate for an OCT-defined 
threshold of DMO severity.
Methods
ethical approval
The lead clinician and Caldicott Guardian at each centre gave 
written approval for extraction of anonymised data. The study 
protocol was approved by the head of research governance at 
the lead clinical centre. This study was conducted in accordance 
with the Declaration of Helsinki and the UK Data Protection 
Act.
data collection
Anonymised data were remotely extracted from 19 centres using 
the same EMR system (Medisoft Ophthalmology, Medisoft, 
Leeds, UK). Each site is the only NHS provider of DMO care 
to their local population and very few patients switch between 
providers or access care privately. Data were extracted through 
the EMR compulsory DR structured assessment module. The 
minimum dataset included: age, visual acuity at baseline and 
at all subsequent visits, injection episodes, timing of cataract 
surgery and proxy-ETDRS/International Clinical Grading system 
grading of retinopathy and maculopathy.
Inclusion criteria
Eyes undergoing cataract surgery from patients with diabetes, 
with retinopathy grade(s) recorded in the 2 years pre-surgery 
and post-surgery, and who had not developed DMO requiring 
treatment prior to study entry (ie, 2 years pre-surgery). For the 
purposes of this study we analysed the development of DMO in 
terms of the requirement for treatment, that is DMO of sufficient 
severity to warrant an intervention; this is referred to as ‘treat-
ment-requiring DMO’ throughout the study. It is recognised that 
some of these cases might have spontaneously resolved without 
treatment, but the term ‘treatment-requiring’ is used to indi-
cate that the severity of DMO was considered sufficient by the 
attending clinician to institute treatment. The EMR mandated 
structured assessment only requires recording of the location of 
retinal thickening, not the causative factor(s). Recorded post-op-
erative episodes of retinal thickening in patients with diabetes 
may therefore include some cases of pseudophakic macular 
oedema (post-operative, cystoid macular oedema). In line with 
the study aims of providing a ‘real world’ analysis, patients were 
included even if they had additional pre-operative risk factors 
(such as history of uveitis) or intra-operative complications.
Analysis
The primary outcome measure was the rate of developing first 
episode of treatment-requiring DMO in relation to timing of 
cataract surgery in the same eye, described both as incident risk 
and as cumulative risk over each successive year. Subsidiary 
analyses included effect of level of retinopathy on the rate of 
developing treatment-requiring DMO in the same eye in relation 
to cataract surgery. Survey of practice included analysis of the 
provision of type of treatments used for DMO and their timing.
results
baseline characteristics
Participants
Data were extracted on 123 968 eyes of 61 984 patients with 
diabetic retinopathy grades (including a grade of no diabetic reti-
nopathy) in the EMR. There were 33 967 male patients, 28 002 
female patients and 15 cases of unrecorded gender.
The inclusion criteria were met for 4850 eyes from 3837 
patients, namely eyes undergoing cataract surgery in patients 
with diabetes, with retinopathy grade(s) recorded in the  2 years 
pre-sugery and post-surgery, and who had not developed DMO 
requiring treatment prior to study entry (ie, 2 years pre-surgery). 
Treatments for DMO included macular laser, injection of intra-
vitreal anti-VEGF therapies (ranibizumab, bevacizumab, afliber-
cept) and injection of intravitreal corticosteroids (triamcinolone, 
Iluvien and Ozurdex).
The study group comprised 1719 eyes with no apparent 
DR, 1034 with mild NPDR, 1527 with moderate NPDR, 165 
with severe NPDR, and 405 with proliferative DR.
rate of developing first episode of treatment-requiring dMo 
in relation to cataract surgery
The rate of developing first episode of treatment-requiring DMO 
in the whole cohort was 3.1% and 2.9% in each of the 2 years 
prior to surgery versus 5.3% and 4.8% in each of the 2  years 
after surgery (p<0.01; see table 1). More detailed analysis by 
3-month intervals demonstrated that the risk of ‘treatment-re-
quiring DMO’ increased sharply after surgery, peaking in the 
3–6 months post-operative period (figure 1). The cumulative 
risk rose from 6.2% for the 24-month pre-operative period to 
14.7% for the full 48-month peri-operative period (see table 2).
effect of retinopathy grade on the risk of developing first 
episode of ‘treatment-requiring dMo’ in relation to cataract 
surgery
The risk of developing ‘Treatment-requiring DMO’ was signifi-
cantly associated with pre-operative grade of retinopathy. In 
the first year after cataract surgery the risk of developing first 
episode of ‘Treatment-requiring DMO’ was 1.0% (no DR seen 
pre-operatively), 5.4% (mild NPDR), 10.0% (moderate NPDR), 
13.1% (severe NPDR) and 4.9% (PDR) (table 1, figure 2). For 
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mild and moderate grades of retinopathy this represented an 
approximate doubling of the risk of DMO compared with the 
year prior to surgery; the relative increase in risk was less great 
for severe NPDR and for PDR, but it is noteworthy that the risk 
of DMO in the severe NPDR group was more than twice that of 
the PDR group.
cumulative risk of developing treatment-requiring dMo over 
time
The cumulative risk of developing ‘Treatment-requiring DMO’ 
was calculated according to the level of retinopathy prior to 
surgery. The cumulative risk varied according to retinopathy 
grade and time in relation to surgery. It should be noted that as 
per the study inclusion criteria no patients had ‘treatment-re-
quiring DMO’ at their baseline (defined as 2 years prior to cata-
ract surgery). Cumulative risk of developing first episode of 
‘Treatment-requiring DMO’ at 4 years of follow-up (ie, 2 years 
post cataract surgery) was 14.7% for the whole cohort, but 
varied significantly according to retinopathy being 1.4% (no DR 
seen pre-operatively), 13.4% (mild NPDR), 29.5% (moderate 
NPDR), 59% (severe NPDR) and 19.1% (PDR) (table 2, 
figure 2).
treatment modalities for dMo
Of the 4850 eyes included in this study, 622 received treatment 
for the first episode of ‘Treatment-requiring DMO’ during the 
study period (ie, up to 2 years post cataract surgery). Macular 
laser was the predominant therapy used both before and 
after cataract surgery, comprising 84.6% vs 68.5% of all first 
treatments for DMO in the 2 years pre-surgery versus 2 years 
post-surgery (figure 3). The proportion of cases treated with 
ranibizumab increased over eightfold from 2.5% to 20.8% of all 
first treatments for DMO; the use of ‘other treatments’ showed 
little change, being 13% vs 10.7% (pre-surgery versus post-sur-
gery respectively).
dIscussIon
This real-world dataset collated from a large number of centres 
across the UK demonstrates the increased rate at which patients 
with diabetes develop DMO in the period after cataract surgery. 
The percentage of eyes developing first episode of ‘treatment-re-
quiring DMO’ increased from 2.9% in the year immediately 
prior to surgery to 5.3% in the first year and 4.8% in the second 
year after surgery; the highest risk period was between 3 and 6 
months after surgery with 1.7% of eyes developing first episode 
of ‘treatment-requiring DMO’ during that 3-month period, 
equating to an annualised risk of 6.8%. The percentage of 
‘ranibizumab-requiring DMO’ which in the UK is based on an 
OCT definition of DMO with a minimum CMT of 400 microns, 
increased from 0.1% for the 2-year period prior to surgery to 
1.5% of eyes for the 2-year period post-surgery.
Our findings provide additional data to suggest that there 
is a real increase in treatment-requiring DMO after cataract 
surgery. This has been a matter of considerable debate, espe-
cially since the ETDRS Report 25 failed to show a significant 
increase with 29% patients being noted to have CSME at their 
study visit occurring prior to cataract surgery and 31% having 
CSME at their study visit occurring post-surgery.9 It should 
be noted however that this study may now be less relevant to 
current practice due to the modernisation of cataract surgery 
(including the widespread adoption of phacoemulsification since 
that time) and advances in the care of diabetic eye disease. Addi-
tionally the population analysed in ETDRS Report 25 differed 
from most studies (including ours) in that it had a very high 
proportion of patients with more advanced retinopathy: PDR 
and/or vitreous haemorrhage was present in 40% of those who 
had a gradeable fundus photograph from the visit immediately 
preceding their cataract operation. A more recent prospective 
study looking at unilateral cataract surgery in 132 eyes (with the 
table 1 Risk of Developing First Episode of Treatment-Requiring diabetic macular oedema (DMO)
time in relation to cataract surgery (months) −24 to −12 −12 to 0 0 to +12 +12 to +24
risk of dMo (%) All eyes (n=4850) 3.1 2.9 5.3 4.8
stratified by etdrs grade*
No DR (n=1719) 0.0 0.0 1.0 0.8
Mild NPDR (n=1034) 2.1 2.6 5.4 5.6
Moderate NPDR (n=1527) 5.4 5.5 10.0 8.9
Severe NPDR (n=165) 11.5 11.0 13.1 11.5
PDR (n=405) 5.9 4.2 4.9 4.2
*Stratification is by proxy-ETDRS/International Clinical Grading system grade of retinopathy at most recent assessment prior to cataract surgery (mild, moderate and severe 
NPDR and PDR retinopathy). Time periods are up to but not including the upper boundary, ie, −24 to −12 equates to any time point from −24 months to 1 day prior to −12 
months. An event occurring at exactly −12 months is included in the −12 to 0 month group. Similarly, patients treated on the day of surgery are included in the 0–12 month 
group. Since development of DMO is a censoring event, the number of eyes at risk reduces over time as follows: 4850 (−24 to −12 months), 4702 (−12 to 0 months), 4565 (0 
to +12 months), 4323 (+12 to +24 months).
NPDR, non-proliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy.
Figure 1 Risk of developing first episode of ‘Treatment-requiring 
diabetic macular oedema (DMO)’ in relation to cataract surgery. Risk of 
developing first episode of ‘Treatment-requiring DMO’ in patients with 
diabetes in the 2 years before and after cataract surgery. Percentages 
given are of risk of ‘treatment-requiring DMO’ in that 3-month period.
 o
n
 11 M
ay 2018 by guest. Protected by copyright.
http://bjo.bmj.com/
Br J O
phthalm
ol: first published as 10.1136/bjophthalmol-2016-309838 on 9 May 2017. Downloaded from 
1676 Denniston AK, et al. Br J Ophthalmol 2017;101:1673–1678. doi:10.1136/bjophthalmol-2016-309838
clinical science
fellow eye acting as control) noted a trend towards higher rate of 
CSME in the operated eye versus the fellow eye (6.1% vs 4.5%) 
within the first 6 months.12 It should be noted that the difference 
between rates of CSME (both pre-operative and post-operative) 
may also reflect the inclusion of patients with milder levels of 
retinopathy in this later study. The findings of our study indi-
cate that this previously observed trend towards higher levels 
of treatment for DMO in the post-operative phase, is indeed 
significant and provides, for the first time, evidence that there 
is a ‘high-risk’ period in the post-operative phase which peaks 
between 3 and 6 months. This dataset is taken using a single data 
capture platform across a large population in the UK, reflecting a 
wide ethnic-mix from urban and rural environments. The EMR 
mandates a structured assessment of DR resulting in an ETDRS 
grading of retinopathy and maculopathy based on the presence 
or absence of clinical signs at each clinic visit.
It is important to note that our study is not directly compa-
rable to earlier studies in that we are not assessing CSME, but 
rather ‘treatment-requiring DMO’. ‘Treatment-requiring DMO’ 
is a clinically relevant group which, while subjective, provides 
an important metric of the burden of disease on the patient and 
the clinical service. The ‘ranibizumab-requiring DMO’ subgroup 
provides an objectively defined disease threshold for DMO due 
to the regulatory requirements in the UK requiring an OCT-de-
fined threshold of DMO with a CMT of >400 microns before 
treatment with ranibizumab is funded. This avoids the subjec-
tivity of clinically-defined CSME, which may show significant 
inter-observer variability. Both the ‘treatment-requiring DMO’ 
group and the ‘ranibizumab-requiring DMO’ subgroup show the 
same significant increase in treatment for DMO the post-oper-
ative phase, and both peak between 3 and 6 months post-oper-
atively. It is recognised that in this analysis  we have considered 
neither the actual level of CMT nor which instrument it has been 
measured on (which may influence the threshold)16; these OCT 
data are not currently available for our dataset but may be avail-
able in future data extractions.
The relatively modest use of ranibizumab as first line treatment 
in this cohort probably reflects the fact that most UK centres 
only adopted its use routinely after the NICE guidance in 2013. 
table 2 Cumulative risk of developing first episode of treatment-requiring diabetic macular oedema (DMO)
time in relation to cataract surgery (months) −24 to −12 −24 to 0 −24 to +12 −24 to +24
cumulative risk of dMo 
(%)
All eyes 3.1 6.2 12.1 14.7
stratified by etdrs grade*
No DR (n=1719) 0.0 0.0 1.0 1.4
Mild NPDR (n=1034) 2.2 4.8 10.7 13.4
Moderate NPDR (n=1527) 5.6 11.8 23.9 29.5
Severe NPDR (n=165) 12.6 26.7 46.0 59.0
PDR (n=405) 6.2 10.9 16.5 19.1
*Stratification is by ETDRS grading of retinopathy at most recent assessment prior to cataract surgery (mild, moderate and severe NPDR and PDR retinopathy). See previous table 
legend regarding upper boundaries of time periods.
NPDR, non-proliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy.
Figure 2 Effect of retinopathy on risk of developing first episode of 
‘Treatment-requiring diabetic macular oedema (DMO)’ in relation to 
cataract surgery. Risk of developing first episode of ‘Treatment-requiring 
DMO’ in patients with diabetes in the 2 years before and after cataract 
surgery. Percentages given are of risk of ‘treatment-requiring DMO’ in 
that 3-month period. Stratification is by ETDRS grading of retinopathy 
at most recent assessment prior to cataract surgery (mild, moderate and 
severe non-proliferative diabetic retinopathy (NPDR) and proliferative 
diabetic retinopathy (PDR) retinopathy). The variability of the ‘Severe 
NPDR’ cohort is likely to be a function of its significantly smaller size 
(n=165) compared with the other cohorts (n=1719 for no apparent DR, 
n=1034 for mild NPDR, n=1527 for moderate NPDR, and n=405 for 
proliferative DR).
Figure 3 Treatment selection for diabetic macular oedema (DMO) 
over time in relation to cataract surgery. Treatment selection for first 
episode of ‘Treatment-requiring DMO’ in patients with diabetes in 
the 2 years before and after cataract surgery. ‘Other’ comprises other 
intravitreal treatments including alternative anti-vascular endothelial 
growth factor (VEGF) agents and intravitreal corticosteroid therapies.
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The increased availability of this drug at later time points of the 
study must be borne in mind when interpreting any increase 
in its usage over time, such as the fact that the proportion of 
cases treated with ranibizumab increased from 2.5% for the 
2 years prior to surgery to 20.8% for the 2 years after surgery. In 
contrast any decline in usage (such as after the observed peak in 
the 4 to 6 month period post-surgery) can be assumed to be real 
(since availability would have increased over this period). The 
treatment data therefore reliably inform us that the risk of devel-
oping DMO exceeding 400 microns peaks in the 4 to 6 month 
post-operative period, which is also in line with the incidence 
of cases of DMO overall. Ideally a future study would take a 
new cohort with study inception after 2013. This would show 
a much higher proportion of ranibizumab (and more recently 
aflibercept) usage both pre-surgery and post-surgery, and would 
provide a more complete estimate of the proportion of ‘treat-
ment-requiring DMO’ which is associated with a macular thick-
ness of greater than 400 microns.
A possible alternative explanation when assessing studies 
reporting progression of diabetic retinopathy and/or macu-
lopathy after cataract surgery is whether this simply reflects 
improved visualisation of the fundus. An advantage of our 
study is that the ranibizumab endpoint reflects an OCT-defined 
measure in a subset of our cohort, which is usually possible 
pre-surgery and post-surgery. We would however recognise 
two limitations. First we do not know how rigorously clinicians 
obeyed the >400 micron limit before offering ranibizumab to 
their patients as we have not extracted the OCT data. Second, 
OCT was not compulsory at all visits so there may be cases of 
DMO with CMT >400 microns which were missed and not 
treated. It may be argued that this was more likely to happen 
pre-operatively due to worse visualisation. We do not think that 
this was a major issue however, as most patients with worsening 
vision and diabetic retinopathy being considered for cataract 
surgery are likely to have had an OCT, although we cannot 
confirm the exact rates of pre-operative OCT scanning in the 
current data extract.
It may be difficult to distinguish pseudophakic (postopera-
tive, cystoid macular oedema), macular oedema from DMO 
post-operatively; the EMR mandated structured assessment only 
requires recording of the location of retinal thickening. Standard 
clinical practice in the UK would have been to use topical steroids 
and/or non-steroidal drops as first line treatment if the clini-
cian believed the problem to be pseudophakic macular oedema 
followed by intravitreal or sub-Tenon’s triamcinolone acetonide 
as second line treatment. Analysis of our study suggests that this 
would only account for a small proportion of the cases seen. 
Intravitreal and sub-Tenon’s triamcinolone together accounted 
for around one-third of the ‘Other Treatment’ category (specif-
ically 12% intravitreal, 20% sub-Tenon’s), and did not increase 
significantly after surgery with ‘Other Treatments’ comprising 
13% vs 10.7% of total treatments (pre-surgery versus post-sur-
gery respectively).
The lack of compulsory pre-operative and post-operative 
OCT and fundus fluorescein angiography (FFA) in all cases is 
one example of the differences between ‘real-world’ studies 
and prospective RCTs. An RCT can provide stringently quali-
ty-assured data, taken on a group of patients with the condi-
tion of interest, accompanied by minimal co-pathology and 
with carefully scheduled visits allowing treatment to be deliv-
ered and monitored under closely controlled conditions. Such 
studies have many advantages, and are valuable particularly for 
licensing studies as they may provide a high signal:noise ratio 
and, if well-designed, have a low risk of bias. They are however 
very expensive and generally deliberately exclude large sections 
of the population for whom the treatment is clinically indicated.
‘Real-world’ studies are of immense value in a number of situ-
ations. First, they provide some indication of how a treatment 
effect seen in the ideal but artificial environment of an RCT 
actually translate into benefits (and adverse events) in a much 
more heterogeneous group of patients in the less controlled 
environment of clinical practice. Second, they provide a mecha-
nism of identifying and investigating rarer conditions, for which 
a suitably scaled RCT would be unaffordable.
Data from ‘real world’ studies can still be quality-assured, 
although not to the same level as an RCT. In our study, the design 
of the EMR system ensures that the data entry is structured, 
key fields are compulsory, and we have demonstrated previ-
ously low rates of missing non-compulsory fields.17 Fields have 
value cut-offs to stop major data entry errors; most minor errors 
may occur in either direction and so with a large sample size it 
is anticipated that these would become negligible. In summary, 
we would argue that any additional ‘noise’ in our study brought 
about by its real world, retrospective design, will be compen-
sated for by the large sample size and multiple physicians and 
hospital.
One of the key questions arising from this study is whether 
this new evidence regarding the risk of post-operative DMO 
should alter practice, particularly regarding frequency (and 
location) of follow-up in the post-operative phase supported 
by the use of OCT to screen for DMO. The follow-up of 
patients with diabetic retinopathy after cataract surgery is very 
variable, being primarily dependent on the level of diabetic 
retinopathy. In the UK and many other countries, patients 
with mild NPDR may only receive the same level of hospital 
follow-up as patients without diabetes. Depending on local 
practice they receive one (or no) hospital reviews before being 
discharged to their community optometrist for post-operative 
refraction. Unless either the patient or the optometrist report 
specific concerns, patients may not receiveany further assess-
ment of their fundus until their annual photographic review 
within the National Diabetic Eye Screening Service. It should 
be noted that this assessment is based on the grading of two-di-
mensional fundus photographs and the recorded level of visual 
acuity, and does not include stereo-photographs or OCT assess-
ment which would assist in the detection of DMO. Our study 
suggests however that the highest risk for the development 
of DMO occurs in the period after the typical timing of the 
first post-operative visit and occurs at a significant rate even in 
those patients that have been assessed as having mild NPDR. It 
may however be possible to further stratify this risk. A  DRCR. 
net study found that at sixteen weeks postoperatively, OCT-de-
fined centre-involving ME developed in 0% of eyes with no 
preoperative DMO versus 10% if eyes had had pre-operative 
non–centre-involving DMO and 12% if eyes had been assessed 
as ‘possible’ centre-involving DMO.18  In this context it is also 
interesting to note that those patients with PDR appeared to 
be relatively protected from developing DMO in the post-op-
erative phase when compared with NPDR. This is interesting 
but should be treated with caution as the numbers in the PDR 
group were significantly lower than in the other groups.
It may be argued that most patients will be aware of a decline 
in visual function, and so should be able to self-report visually 
significant DMO; indeed the NICE (UK) threshold is, in part, 
based on this equating to a visually significant difference. It is 
well known however that many patients may ignore the changes 
in one eye, particularly where reasonable vision is retained in the 
other eye.19 There may be therefore  an argument for providing 
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a further OCT-based assessment, whether in the community or 
in the hospital eye clinic, at around 4 months post-operatively to 
screen for the development of DMO, and to provide the oppor-
tunity for early treatment.
In summary, this analysis of a real world dataset achieved at 
a large number of centres across the UK indicates an increased 
rate of developing visually significant DMO in the post-operative 
phase, with a particularly high risk from 3 to 9 months. The UK 
requirement for an OCT-defined threshold of DMO to access 
ranibizumab treatment, and the presence of a clear post-operative 
DMO spike in this cohort provides further evidence that this is 
a real increase in DMO and not just an issue of visualisation. We 
would recommend that assessment prior to cataract surgery for 
any patient with diabetes should include a record of DR severity 
status and a macular OCT of both eyes, while recognising that the 
lens opacities may limit assessment in some eyes. There may also 
be a role for increased monitoring of patients with even relatively 
mild diabetic retinopathy during the post-operative phase to help 
detect DMO and enable earlier treatment.
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